← SynDRA
ARTEMETHER
SynDRA canonical compound SYN0020186 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | ATP1A1 | CYP2B6 | CYP2C19 | CYP3A5 |
| Mechanism of action | antimalarial agent |
| Indication | malaria |
| Disease area | infectious disease |
All known targets
- ATP1A1
- CYP2B6
- CYP2C19
- CYP3A5
Mechanisms of action (all sources)
- ATP1A1 BINDER
- DNA synthesis inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PTGES2
- ACHE
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LMNA
- LCK
- KCNH2
- HTR6
- MMP1
- HTR2C
- HTR2B
- HTR2A
- HRH2
- HRH1
- HMGCR
- HDAC6
- GMNN
- FYN
- MC5R
- MMP9
- ADORA1
- NPY1R
- TBXAS1
- TACR2
- TACR1
- SLC6A4
- SLC6A3
- SLC6A2
- SIGMAR1
- PTPRC
- PTGS2
- PTGS1
- PTAFR
- PRKCA
- PPP3CA
- PDE5A
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP3A7
- KCMB2
- KSYK
- SYK
Drug classes
- Antimalarial
- Anti-Infective Agents
- Antimalarials
- Antiparasitic Agents
- Antiprotozoal Agents
- antimalarial agent
- Anthelmintics
- Antineoplastic Agents
- Antiplatyhelmintic Agents
- Antiviral Agents
- Schistosomicides
ATC classes
Cross-references
Synonyms
- COARTEM
- artemos
- artenam
- artesaph
- dihydroartemisinin methyl ether
- falcidol
- gvither
- malartem
- beta-Artemether
- Artemetero
- .beta.-artemether
- Artemetherum
- Artesaph
- Falcidol
- Gvither
- Larither
- Malartem
- Paluther
- NSC-665970
- NSC-759820
- SM 224
- SM224
- Artemether component of coartem
- Artemetheri
- Dihydroartemisinin impurity g
- Artemether[inn]
- Artemos
- Artenam
- Artesian
- Artimist
- Artmether
- Rither
- Arteannuin ether
- Artemether [INN]
- Artemisininelactol methyl ether
- Dihydroartemisinin methyl ether
- Dihydroquinghaosu methyl ether
- SM-224
Reported adverse events
- Abdominal pain
- Arthralgia
- Aspartate aminotransferase increased
- Asthenia
- Chills
- Cough
- Dizziness
- Fatigue
- Headache
- Hepatomegaly
- Hypersensitivity
- Infection
Look up ARTEMETHER in the interactive SynDRA portal →